Lower mortality with andexanet alfa vs 4-factor prothrombin complex concentrate for factor Xa inhibitor-related major bleeding in a U.S. hospital-based observational study.

Paul P DobeshGregory J FermannMary J ChristophBruce KochEva LesénHungta ChenBelinda LovelaceTheresa DettlingMark DaneseJulie UlloaSherry DaneseCraig I Coleman

Published in: Research and practice in thrombosis and haemostasis (2023)

In this large observational study, treatment with andexanet alfa in patients hospitalized with rivaroxaban- or apixaban-related major bleeds was associated with 50% lower odds of in-hospital mortality than 4F-PCC. The magnitude of the risk reduction was similar in ICH and GI bleeds.

Keyphrases

atrial fibrillation
end stage renal disease
venous thromboembolism
ejection fraction
newly diagnosed
chronic kidney disease
replacement therapy
prognostic factors
peritoneal dialysis
pulmonary embolism
type diabetes
cardiovascular disease
coronary artery disease
patient reported